News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Clears 22nd Century Group, Inc.'s X-22 IND For Phase II-B Smoking Cessation Clinical Trial



7/22/2011 10:50:49 AM

WILLIAMSVILLE, N.Y.--(BUSINESS WIRE)--22nd Century Group, Inc. (OTCBB: XXII), a company focused on smoking cessation and tobacco harm reduction products, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) Application to conduct a Phase II-B clinical trial using X-22, a prescription smoking cessation aid in development.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES